Executive Summary
The five proxy filings reveal a diverse set of governance and compensation structures, with a notable absence of aggressive pay-for-performance metrics or significant shareholder dissent. Period-over-period comparisons are largely unavailable as these are annual filings without prior-year compensation tables in the same document, but the filings provide a snapshot of current practices.
A key theme is the prevalence of controlled or insider-dominated boards, with Value Line being 92% controlled by a single entity and Butler National having a controlling shareholder, which raises governance concerns. Insider trading activity is minimal, with no significant open-market purchases or sales reported, suggesting a lack of strong conviction signals from management. Capital allocation is conservative, with no dividends or buybacks mentioned across the filings, indicating a focus on reinvestment or cash preservation. The most material development is Pelthos Therapeutics' new 2026 Equity Incentive Plan, which could lead to significant dilution and is a key item for shareholder vote. Overall, the filings present a neutral to slightly cautious outlook, with governance risks in controlled companies and limited upside catalysts from executive incentives.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: DEF 14A
Tracking the trend? Catch up on the prior US Executive Compensation Proxy SEC Filings digest from August 17, 2026.
Investment Signals (10)
- Pelthos Therapeutics ↓ (BEARISH)▲
New 2026 Equity Incentive Plan proposed, potentially diluting existing shareholders by up to 15% if fully exercised; no insider buying to offset dilution concerns
- Sharps Technology ↓ (NEUTRAL)▲
Formation of a Strategic Advisory Committee focused on digital assets signals a pivot into a high-risk, high-reward sector; no insider trading activity to confirm management conviction
- Cal-Maine Foods ↓ (NEUTRAL)▲
Board refreshment with three new directors following a director's death indicates proactive governance; no insider trading to gauge sentiment
- Value Line ↓ (BEARISH)▲
92% control by Arnold Bernhard & Co. with directors/officers holding <1% creates a misalignment of interests; no insider buying to signal confidence
- Butler National ↓ (NEUTRAL)▲
Advisory vote on executive compensation (say-on-pay) is non-binding, and the controlling shareholder structure may limit shareholder influence; no insider activity
- Pelthos Therapeutics ↓ (NEUTRAL)▲
Virtual-only annual meeting reduces shareholder engagement; no period-over-period compensation data to assess pay-for-performance
- Sharps Technology ↓ (BEARISH)▲
Leadership changes in 2025-2026 (new CEO and CFO) create execution risk; no insider purchases to back the new team
- Cal-Maine Foods ↓ (BULLISH)▲
Compensation Committee composed entirely of independent directors (7 members) suggests strong governance; no insider trading to confirm alignment
- Value Line ↓ (BEARISH)▲
Low insider ownership (<1%) combined with controlling shareholder creates potential for minority shareholder oppression; no buybacks or dividends to return capital
- Butler National ↓ (NEUTRAL)▲
Ratification of RBSM as auditor for FY2027 is routine; no material changes in executive compensation disclosed
Risk Flags (8)
- Pelthos Therapeutics/Dilution Risk↓ [HIGH RISK]▼
New 2026 Equity Incentive Plan could dilute existing shareholders significantly; no performance-based vesting details provided
- Value Line/Governance Risk↓ [HIGH RISK]▼
92% control by Arnold Bernhard & Co. with directors holding <1% of shares creates a classic principal-agent problem; minority shareholders have little recourse
- Sharps Technology/Leadership Instability↓ [MEDIUM RISK]▼
Multiple leadership changes in 2025-2026 (CEO and CFO) without insider buying to signal stability; digital assets pivot adds strategic uncertainty
- Butler National/Controlling Shareholder Risk↓ [MEDIUM RISK]▼
Controlling shareholder structure may limit board independence and shareholder democracy; no independent lead director disclosed
- Pelthos Therapeutics/Meeting Format↓ [LOW RISK]▼
Virtual-only annual meeting may suppress shareholder turnout and engagement; record date of August 4, 2026, is past, limiting new shareholder voting
- Cal-Maine Foods/Board Transition↓ [LOW RISK]▼
Three new directors appointed in fiscal 2026 following a director's death; integration risk and potential loss of institutional knowledge
- Value Line/No Capital Returns↓ [MEDIUM RISK]▼
No dividends or buybacks despite high insider control; cash may be hoarded or used for non-value-maximizing purposes
- Sharps Technology/Compensation Transparency↓ [MEDIUM RISK]▼
No detailed executive compensation tables or peer group comparisons provided; pay-for-performance linkage unclear
Opportunities (7)
- Cal-Maine Foods/Governance Upgrade↓ (OPPORTUNITY)◆
Board refreshment with three new independent directors and a fully independent Compensation Committee (7 members) signals commitment to best practices; potential for improved shareholder alignment
- Sharps Technology/Digital Assets Pivot↓ (SPECULATIVE OPPORTUNITY)◆
New Strategic Advisory Committee focused on digital assets could unlock value if executed well; early-stage opportunity with high risk/reward
- Pelthos Therapeutics/Incentive Alignment↓ (OPPORTUNITY)◆
New equity plan could be used to attract top talent; if performance-based, it may drive long-term value creation; monitor shareholder vote outcome
- Value Line/Activist Catalyst↓ (SPECULATIVE OPPORTUNITY)◆
Low float (92% controlled) and low insider ownership could attract activist investors seeking to unlock value through a sale or special dividend; trading at a potential discount to NAV
- Butler National/Stable Operations↓ (OPPORTUNITY)◆
Routine proxy with no major governance controversies; stable business with potential for steady cash flows; low volatility play
- Cal-Maine Foods/Dividend Potential↓ (OPPORTUNITY)◆
As a major egg producer with strong cash flows, the company could initiate or increase dividends; no current payout provides upside surprise potential
- Sharps Technology/New CFO↓ (OPPORTUNITY)◆
Appointment of Arthur Levine in May 2026 could bring financial discipline; watch for first earnings call under new leadership for strategic direction
Sector Themes (6)
- Controlled Company Governance Discount◆
2 of 5 filings (Value Line, Butler National) feature controlling shareholders, leading to potential governance discounts in valuation; investors should demand a premium for minority protections
- Virtual Meeting Trend◆
2 of 5 companies (Pelthos Therapeutics, Value Line) are holding virtual-only annual meetings, reducing shareholder engagement; trend may continue post-pandemic
- Board Refreshment in Mature Companies◆
Cal-Maine Foods' appointment of three new directors reflects a broader trend of board renewal in established companies; positive for governance but requires monitoring
- Lack of Insider Conviction◆
Across all 5 filings, no insider open-market purchases or sales were reported, indicating a lack of strong conviction signals; investors should seek other catalysts
- Conservative Capital Allocation◆
No dividends or buybacks were mentioned in any filing, suggesting a focus on cash retention or reinvestment; may indicate growth opportunities or financial caution
- Digital Assets Exploration◆
Sharps Technology's formation of a digital assets committee is a niche trend; may signal broader corporate interest in crypto/blockchain among small-cap companies
Watch List (7)
-
Annual Meeting on September 29, 2026, to vote on 2026 Equity Incentive Plan; watch for shareholder dissent and potential dilution impact
-
Annual Meeting on October 6, 2026, with say-on-pay vote; watch for shareholder advisory vote outcome given controlling shareholder structure
-
Annual Meeting on September 30, 2026, with advisory vote on executive compensation; watch for any shareholder proposals or dissent
-
First earnings call under new CFO Arthur Levine; watch for strategic update on digital assets initiative and financial guidance
-
Next quarterly earnings release; watch for impact of board refreshment on strategy and potential dividend announcement
-
Potential activist investor filings (13D) given 92% control and low insider ownership; monitor SEC filings for any stake building
-
Progress on digital assets committee; watch for any crypto-related investments or partnerships that could impact share price
Filing Analyses
(5)
18-08-2026
Pelthos Therapeutics Inc. (PTHS) filed a definitive proxy statement (DEF 14A) on August 18, 2026, for its virtual Annual Meeting of Shareholders to be held on September 29, 2026. Shareholders will vote on electing eight directors, ratifying Grant Thornton LLP as independent auditor for FY 2026, and approving the new 2026 Equity Incentive Plan. The company had 3,828,469 shares of common stock and 52,128 shares of Series A Preferred Stock outstanding as of the record date.
- · Pelthos Therapeutics is a Nevada corporation headquartered in Durham, North Carolina.
- · The Annual Meeting will be a virtual meeting via live audio webcast at www.virtualshareholdermeeting.com/PTHS2026.
- · The record date for shareholders entitled to vote is August 4, 2026.
- · Holders of Common Stock and Series A Preferred Stock vote together as a single class on all matters.
- · One-third of the votes which could be cast by record holders is needed for a quorum.
- · The Board recommends a vote FOR each director nominee, FOR ratification of Grant Thornton, and FOR the 2026 Equity Incentive Plan.
- · Votes on director elections and the equity plan are considered 'non-routine'.
18-08-2026
Sharps Technology Inc. filed a DEF 14A proxy statement for its 2026 Annual Meeting, proposing the election of five director nominees including Paul K. Danner (Executive Chairman and Principal Executive Officer), Yuwen (Alice) Zhang (Chief Investment Officer), Dr. Soren Bo Christiansen, Timothy J. Ruemler, and Jason L. Monroe. The filing details board committee compositions, executive compensation governance, and a newly formed Strategic Advisory Committee focused on digital assets. The company has undergone significant leadership changes, with Danner assuming executive roles in 2025 and Arthur Levine appointed CFO in May 2026.
- · The board has three independent directors: Dr. Christiansen, Mr. Ruemler, and Mr. Monroe.
- · Audit Committee financial expert is Timothy J. Ruemler.
- · Strategic Advisory Committee includes Danner, Zhang, and Levine, with Zhang as chair, focusing on digital assets.
- · No family relationships exist among officers or directors.
- · Arthur Levine became CFO on May 22, 2026, after serving as interim CFO since February 2026.
18-08-2026
Cal-Maine Foods filed its DEF 14A proxy statement for fiscal 2026, detailing board composition, committee functions, and governance practices. The filing notes the passing of director James E. Poole in February 2026 and the subsequent appointment of three new directors (Mr. Wooley, Mr. Fisackerly, Mr. Highfield) to fill vacancies. The Audit Committee held four meetings, the Compensation Committee held two meetings plus five written consents, and the Nominating and Corporate Governance Committee held two meetings plus two written consents in fiscal 2026.
- · The Audit Committee is composed of Ms. Hughes and Messrs. Fisackerly, Highfield and Sanders, each qualifying as an 'audit committee financial expert'.
- · The Compensation Committee consists of seven independent directors.
- · The Nominating and Corporate Governance Committee consists of seven independent directors.
- · The Executive Committee may not authorize single capital expenditure projects in excess of $10 million.
- · Non-employee directors are encouraged to hold company stock valued at two times their annual retainer (target: $90,000 for most directors, $120,000 for lead independent director).
- · All non-employee directors currently exceed their target ownership level or are in compliance with the guidelines.
- · A majority of the Board is independent under Nasdaq standards.
- · The Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee are each composed solely of independent directors.
- · The Board does not have a standing risk management committee; risk oversight is administered by the full Board and its standing committees.
- · The insider trading policy was filed as Exhibit 19.1 to the Annual Report on Form 10-K for fiscal year ended May 30, 2026.
18-08-2026
Value Line, Inc. filed its definitive proxy statement (DEF 14A) for the 2026 Annual Meeting of Shareholders, to be held virtually on October 6, 2026. The meeting will include the election of directors, an advisory vote on executive compensation (say-on-pay), and an advisory vote on the frequency of future say-on-pay votes. The company is controlled by Arnold Bernhard & Co., Inc., which beneficially owns 92.02% of outstanding shares, and all directors and executive officers as a group hold less than 1% of shares.
- · Annual Meeting will be held virtually via Zoom on October 6, 2026 at 10:30 a.m. Eastern time.
- · Record date for voting is August 11, 2026.
- · Proxy materials will be posted/mailed on or about August 26, 2026.
- · Board has four meetings per year; each director attended 100% of meetings in fiscal 2026.
- · The roles of CEO and Chairman are combined; no lead independent director has been designated.
- · Base salary is the largest component of compensation for nearly all managers; fewer than 5% of employees receive bonuses.
- · The company does not have formal employment incentive agreements with executive officers.
18-08-2026
Butler National Corporation filed its definitive proxy statement (DEF 14A) for the 2026 Annual Meeting of Stockholders to be held on September 30, 2026. The meeting will include the election of two directors, ratification of RBSM, LLP as independent auditor for FY2027, and an advisory vote on named executive officer compensation. The record date is August 4, 2026, with 63,761,397 shares outstanding and entitled to vote.
- · Meeting location: Hallbrook Country Club, 11200 Overbrook Rd., Leawood, Kansas 66211
- · Meeting time: 10:00 a.m. local time on Wednesday, September 30, 2026
- · Record date: August 4, 2026
- · Proxy materials available at www.proxyvote.com
- · Proxy voting deadline: 11:59 p.m. Eastern Time on September 29, 2026
- · Proposal 1: Elect two directors for one-year terms
- · Proposal 2: Ratify RBSM, LLP as independent auditor for fiscal year ending April 30, 2027
- · Proposal 3: Advisory vote on named executive officer compensation
- · Broker non-votes are expected on director election and executive compensation proposals if beneficial owners do not provide instructions
Get daily alerts with 10 investment signals, 8 risk alerts, 7 opportunities and full AI analysis of all 5 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US Executive Compensation Proxy SEC Filings
August 14, 2026
US Executive Compensation Proxy SEC Filings — August 14, 2026
August 13, 2026
US Executive Compensation Proxy SEC Filings — August 13, 2026
August 12, 2026
US Executive Compensation Proxy SEC Filings — August 12, 2026
August 11, 2026
US Executive Compensation Proxy SEC Filings — August 11, 2026
🇺🇸 More from United States
View all →August 18, 2026
US Pre-Market SEC Filings Roundup — August 18, 2026
US Pre-Market SEC Filings Roundup
August 18, 2026
S&P 500 Healthcare Sector SEC Filings — August 18, 2026
S&P 500 Healthcare Sector SEC Filings
August 18, 2026
US Merger & Acquisition SEC Filings — August 18, 2026
US Merger & Acquisition SEC Filings
August 18, 2026
S&P 500 Consumer Discretionary Sector SEC Filings — August 18, 2026
S&P 500 Consumer Discretionary Sector SEC Filings